Cheers erupted at the San Diego Convention Center last Wednesday as attendees watched Brazil defeat Scotland in the FIFA World Cup, but for many at the BIO International Convention, biotechnology took center stage over sports. The event marked the 50th anniversary of the biotech industry, drawing participants to network and discuss deals during a period described as optimistic by industry leaders.
Insilico CEO Alex Zhavoronkov contrasted biotech's life-saving work with professional sports, saying, “Sorry, just 22 guys on the field kicking a ball. Can you imagine a job being a football player? For us, we’re saving lives. What are they doing? Entertaining. Grown men making millions of dollars. This is much more important.”
Kyverna Therapeutics CEO Warner Biddle said there was “a tremendous amount of positive energy about how far we’ve come,” highlighting progress made over five decades. John Crowley, CEO of BIO, reflected on Genentech’s founding as an example of American entrepreneurial spirit: “[This is] an industry that’s born of an entrepreneurial spirit, one that’s uniquely American-born and still American-led.”
Maha Radhakrishnan from Sofinnova Investments noted improved market sentiment with about 18 initial public offerings in the sector so far this year and numerous high-profile mergers and acquisitions—including $30 billion spent by Eli Lilly—fueling innovation. Maggie O’Toole from LabCentral said international interest in smaller companies has increased and described strong energy at her first BIO convention outside Boston.
Rachel Lane from Xaira Therapeutics credited BIO for fostering deeper conversations among colleagues compared to virtual meetings, saying these organic interactions provided valuable insights into dealmaking strategies.
Despite overall optimism, Biddle observed that reflecting on past achievements alone was insufficient due to increasing international pressures—particularly from China’s growing presence in biotech discussions. Zhavoronkov expressed frustration about frequent focus on China during panels but acknowledged its significance to industry strategy.
Crowley addressed these concerns directly: “We need to continue to nurture and advance an ecosystem where science entrepreneurs and technology visionaries can combine with those who fund private capital into promising biotech ventures... This is how we will outcompete China and ensure that cures and treatments aren’t treated as a tool in a geopolitical battle.” He called for renewal of entrepreneurial spirit as key to maintaining U.S. leadership in biotechnology.
